Video
Advice to physicians on implementing immunotherapy in their practice
Author(s):
Video Player is loading.
In this video, Susan F. Slovin, MD, PhD, discusses considerations that physicians should know when they are beginning to implement immunotherapy in their practice, which are ideas associated with a presentation that she gave at the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies. Slovin is a medical oncologist at the Memorial Sloan Kettering Cancer Center in New York City, New York.
Related Videos
Rana McKay, MD, on persistence and adherence to relugolix for prostate cancer
Neeraj Agarwal, MD, on talazoparib/enzalutamide efficacy by HRR gene mutation status
Dr Louise Kostos on the rapidly evolving prostate cancer treatment landscape
An expert’s view on combination ARPI/ADT and long-term toxicity in prostate cancer
Rana McKay, MD, on the role of radium-223 in the modern era
Dr Louise Kostos discusses PSA kinetics in mHSPC
The importance of PSADT in high-risk, biochemically recurrent prostate cancer
Neeraj Agarwal, MD, outlines data on enzalutamide plus talazoparib in mCRPC
Expert discusses triplet regimens in metastatic hormone-sensitive prostate cancer
Alicia Morgans, MD, MPH, on PSADT awareness and prostate cancer treatment initiation
Related Content
